Abstract
Background and Introduction: Carcinoma breast is the most common cause of malignancy related mortality in developed countries in our country it is the second most common malignancy. Hormones such as estrogen,progesterone play a vital role in functioning and regulation of epithelial lining of the breast and endometrium. Estrogen and progesterone receptor status is a very important predictive marker in prognosis of the malignancy.
Aims and Objective: To study the histomorphological prognostic factors such as, tumorsize, histological type number of positive axillary lymph nodes, histological grading and correlate with ER/PR status and their role in systemic therapy decision making.
Materials and Method: The study included 110 patients who were admitted with diagnosis of carcinoma breast in surgical wards of Krishna hospital, their histomorphological prognostic factors were studied by histopathological examination and ER/PR status studied by immunohistochemistry and correlated, staging was done for the therapeutic decision making. This study was done over the period from October 2016 to June 2018.
Results: Patients with low Grade tumors (I and II),smaller tumor size, less positive axillary lymph nodes and showed ER/PR positive status .Age was an important factor, ER/PR status was more negative in younger age group, Poorly differentiated tumors (Grade III) showed ER/PR negative status irrespective of the age.
Staging of the tumor was done in order to facilitate the theraptic decision making, out of which majority of patients(50.00%) would benefit only from hormonal therapy,(40.00%) would need a combination a of hormonal and chemotherapy,(9.00%) of patients would benefit only from chemotherapy.
Conclusion: Patients with both ER/PR positive status showed better grade, less aggressive, fewer positive lymph nodes and showed better prognosis to hormonal therapy as compared to patients with ER/PR negative status.
Hence a combination of histopathological and immunohistochemistry studies provides a valuable predictive tool for the prognosis of the patient with carcinoma breast.
References
- Bhagat VM, Jha BM, Patel PR. Correlation of hormonal receptor and Her-2/neu expression in breast cancer : A study at tertiary care hospital in south Gujrat. National Journal of Medical Research. 2012; 2(3):295298.
- Harrison AP, Srinivasan K, Binu VS, Vidyasagar MS, Nair S. Int J Collab Res Intern Med Public Health. 2010; 2(4):109-116.
- Leong SPL, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS et al. Is breast cancer the same in disease in Asian and western countries?. World J Surg. 2010; 34:2308-2324.
- Shrigondekar P, Desai S, Bhosale S, Mankar D, Badwe A. Study of hormone receptor status of breast carcinoma and its correlation with the established prognostic markers. I J H S R. 2012; 1(2):109-116.
- Hoda SA. Invasive ductal carcinoma: Assessment of prognosis with morphologic and biologic markers. In: Hoda SA, Brogi E, Koerner FC, Rosen PP, editors. Rosen’s Breast Pathology. 4th Philadelphia: Lippincott Williams & Wilkins; 2014: 413 - 456.
- Biganzoli L. Prognostic and predictive factors. In: Castiglione M, Piccart M editor. Adjuvant Therapy for Breast Cancer. Cancer Treatment and Research, vol 151. Boston: Springer; 2009: 13-30.
- Dowsett M, Miller W. Estrogen and progesterone receptor testing for prognosis and prediction . In: Harris JR, Lippman ME, Morrow M, Osborne CK . Disease of the breast. 5th Philadelphia: Wolters Kluwer ; 2014: 411- 421.
- Faheem M, Mahmood H, Khurram M, Qasim U, Irfan J. Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and it’s association with tumor characteristics and menopausal status in a breast cancer cohort from northern Pakistan. 2012 ; 6(283):1-8.
- De SK, PS, Pruthvi, GU K, Nandyal SN, H SJ. Estrogen, progesterone and human epidermal growth factor receptor-2 in malignant breast lesions : A 5 year study in a tertiary care hospital of Karnataka. Indian Journal of Pathology and Oncology. 2015; 2(4):230-235.
- Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh LD et al. Progesterone receptor by immunohisto-chemistry and clinical outcome in breast cancer: a validation study. Modern Pathology. 2004 ;17:1545-1554.
- Dutta V, Chopra GS, Sahai K, Nema SK. Hormone receptors, Her2/neu and chromosomal aberrations in breast cancer. M J A F I. 2008; 64:11-15.
- Almasri NM, Hamad MA. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordon. Breast Cancer Res. 2005 ; 7(5) : 598-604.
- GulamNS , Junaid NS , Raja N, Rayees YS , Faroze AK, Abid AS et al. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph nodeinvolvement. Asian Pacific J Cancer Prev. 2012;13(10):50475052.
- Donegan WL. Prognostic factors: Stage and receptor status in breast cancer. Cancer. 1992 ;70:1755-1764.
- Reiner A, Reiner G, Spona J, Schemper M, Holzner JH. Histopathologic characterization of human breast cancer in correlation with estrogenreveptor status. Cancer. 1988; 61:1149-1154.
- Zafrani B, Aubriot M, Cremoux P, Rycke Y, Nicolas A, Boudou E et al. High sensitivity and specifying of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Hisopathology2000;37:536-45.
- Onitilo AA, Engel MJ, Greenlee TR, Mukesh NB. Breast Cancer subtypes based on ER/PR and HER-2 expression : Comparison of Clinicopathologic features and survival. Clinical Medicine and Research ;7(1/2):4-13
- Geethamala K, Murthy VS, Vani BR, Rao S. Histopathological grade versus hormone receptor status in breast carcinoma – treasure the past. I J B R. 2015; 6(07):466-471
- Chua DYF, Pang MWY, Rauf A, AWS, Chan S. Correlation of steroid receptors with histologic differentiation in mammary carcinoma: A Singapore experience. Cancer.1985; 56:2228-2234.
- Senkus E, Kyriakides S, Penault-Llorca F, et al.: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 (Suppl 6): vi7-23, 2013.
- Gupta D, Gupta V, Marwah N, Gill M, Gupta S, Gupta G et al. Correlation of hormone receptor expression with histologic parameters in benign and malignant breast tumors. Iran J Pathol. 2015; 10(1):23-34.
- Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 347-76.
- Al-Nuaimy WMT, Ahmed AH, Al-Nuaimy HAA. Immunohistochemical evaluation of triple markers (ER, PR and HER-2/neu) in carcinoma of the breast in the north of Iraq. Donn J Med lab Diagn. 2015;1(1):52-60.
- Taucher S, Rudas M, Madar RM, Gnant M, Dubsky P, BachleitnerT,et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer. 2003; 98(12):2547-2553.
- Al Zaman AS, Mughal SA, Al Zaman YS, Al Zaman ES. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. Saudi Med J. 2016; 37(1):37-42.
- Nomura Y, Miura S, Koyama H, Enomoto K, Kasumi F, Yamamoto H et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer: A univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the study group for the Japanese breast cancer society on hormone receptors and prognosis in breast cancer. Cancer. 1992; 69(1):153-164.
- Rao C, Shetty J, Prasad KH. Morphological profile and receptor status in breast carcinoma: An institutional study. J Cancer Res Ther. 2013; 9(1):44-49.
Corresponding Author
Dr Rajath Rakshit.R
PG Student
DOI: https://dx.doi.org/10.18535/jmscr/v7i2.169
